Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Reumatol Clin ; 15(5): 252-257, 2019.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-30522944

RESUMO

AIMS: To describe the methodology of REAPSER (Spanish Registry of Recent-onset Psoriatic Arthritis), its strengths and limitations. The aim of this study is to identify prognostic factors for the clinical and radiographic course in a cohort of patients with psoriatic arthritis (PsA) diagnosed within 2years of symptom evolution. METHODS: Multicenter, observational and prospective study (with 2-year follow-up including annual visits). Baseline visit intended to reflect patient situation before the disease course was modified by treatments prescribed in rheumatology departments. Patients were invited to participate consecutively in one of their routine visits to the rheumatologist. 211 patients were included. Following data were collected: sociodemographic variables; employment situation; family history; personal history and comorbidities; anthropometric data; lifestyle; use of healthcare services; clinical situation at the time of PsA diagnosis; joint involvement and spinal pain; pain and overall assessment; enthesitis, dactylitis and uveitis; skin and nail involvement; functional situation and quality of life; radiographic evaluation; analytical determinations; treatment; axial and peripheral flare-ups. CONCLUSIONS: The REAPSER study includes a cohort of patients with recent-onset PsA, before the disease course was modified by disease-modifying antirheumatic drugs prescribed in rheumatology departments. Exhaustive information collected in each visit is expected to be an important data source for future analysis.

2.
Reumatol. clín. (Barc.) ; 11(1): 3-8, ene.-feb. 2015. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-132355

RESUMO

Objetivos. Describir la estrategia terapéutica óptima de uso de metotrexato en AR sobre dosis inicial, vía de administración, incremento y disminución de dosis, seguimiento del paciente y uso de ácido fólico/folínico. Material y método. Once expertos plantearon los interrogantes clínicos a resolver. Se realizó una búsqueda bibliográfica sistemática. Los contenidos fueron seleccionados en una sesión de trabajo y el nivel de acuerdo se estableció posteriormente en una ronda de consenso vía correo. Resultados. La dosis de inicio de metotrexato no debe ser < 10 mg/semana, preferentemente por vía oral, considerando la vía parenteral como alternativa según el cumplimento, ineficacia o efectos secundarios gastrointestinales, polimedicación, obesidad (si requiere dosis > 20 mg/semana), preferencias del paciente, enfermedad muy activa o para evitar errores de medicación. Se cambiará a la vía parenteral cuando haya ineficacia, toxicidad gastrointestinal, incumplimiento o por coste-efectividad antes de pasar a fármacos más caros; y a la inversa, según preferencias del paciente, intolerancia a inyectables, reducción de dosis < 7,5 mg/semana, ineficacia, bajo cumplimiento o efectos adversos gastrointestinales. Se realizará escalada rápida de dosis si la respuesta es inadecuada hasta los 15-20 o, incluso, 25 mg/semana en unas 8 semanas, con incrementos de 2,5-5 mg. La reducción se realizará según la dosis a la que estuviera el paciente, con disminuciones de 2,5-5 mg cada 3-6 meses. El seguimiento del paciente deberá realizarse cada 1-1,5 meses hasta la estabilidad y luego cada 1-3 meses. Conclusiones. Este documento pretende resolver algunos interrogantes clínicos habituales y facilitar la toma de decisiones en la AR tratada con metotrexato (AU)


Objectives, To describe the optimal therapeutic strategy for use of methotrexate in RA patients over the initial dose, route of administration, dose increase and decrease, patient monitoring, and use of folic/folinic acid. Materials and methods. Eleven clinical experts proposed some questions to be solved. A systematic literature search was conducted. The contents were selected in a work session and subsequently validated via email to establish the level of agreement. Results. The initial dose of methotrexate should not be <10 mg/week, preferably orally, but the parenteral route is considered as an alternative due to compliance, non-effectiveness of treatment or gastrointestinal side effects, polypharmacy, obesity (if required doses are >20 mg/week), patient preference, very active disease or to avoid administration errors. Changing to a parenteral administration is proposed when the oral route is not effective enough, gastrointestinal toxicity appears, there is non-compliance or due to cost-effectiveness reasons before using more expensive drugs. On the contrary, due to patient preferences, intolerance to injections, dose reduction <7.5 mg/week, non-effectiveness of the route, poor compliance or gastrointestinal side effects. There should be a rapid dose escalation if inadequate responses occur up to 15–20 or even 25 mg/week in about 8 weeks, with increments of 2.5–5 mg. The reduction will be carried out according to the dose the patient had, with decreases of 2.5–5 mg every 3–6 months. Patient monitoring should be performed every 1–1.5 months until stability is reached and then for every 1–3 months. Conclusions. This document pretends to solve some common clinical questions and facilitate decision-making in RA patients treated with methotrexate (AU)


Assuntos
Humanos , Masculino , Feminino , Artrite Reumatoide/tratamento farmacológico , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Dosagem/métodos , Dosagem/prevenção & controle , Alocação de Custos , Custos e Análise de Custo/métodos , Artrite Reumatoide/economia , Formas de Dosagem/normas
3.
Reumatol Clin ; 11(1): 3-8, 2015.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-24746914

RESUMO

OBJECTIVES: To describe the optimal therapeutic strategy for use of methotrexate in RA patients over the initial dose, route of administration, dose increase and decrease, patient monitoring, and use of folic/folinic acid. MATERIAL AND METHOD: Eleven clinical experts proposed some questions to be solved. A systematic literature search was conducted. The contents were selected in a work session and subsequently validated via email to establish the level of agreement. RESULTS: The initial dose of methotrexate should not be <10mg/week, preferably orally, but considering the parenteral route as an alternative due to compliance, non effectiveness of treatment or gastrointestinal side effects, polypharmacy, obesity (if required doses are >20mg/week), patient preference, very active disease or to avoid administration errors. Changing to a parenteral administration is proposed when the oral route is not effective enough, gastrointestinal toxicity appears, there is non-compliance or due to cost-effectiveness reasons before using more expensive drugs. On the contrary, due to patient preferences, intolerance to injections, dose reduction <7.5mg/week, non effectiveness of the route, poor compliance or gastrointestinal side effects. There should be a rapid dose escalation if inadequate responses occurr up to 15-20 or even 25mg/week in about 8 weeks, with increments of 2.5-5mg. The reduction will be carried out according to the dose the patient had, with decreases of 2.5-5mg every 3-6 months. Patient monitoring should be performed every 1-1.5 months until stability and then every 1-3 months. CONCLUSIONS: This document pretends to solve some common clinical questions and facilitate decision-making in RA patients treated with methotrexate.


Assuntos
Antirreumáticos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Metotrexato/administração & dosagem , Administração Oral , Antirreumáticos/uso terapêutico , Relação Dose-Resposta a Droga , Esquema de Medicação , Monitoramento de Medicamentos , Humanos , Injeções , Metotrexato/uso terapêutico , Resultado do Tratamento
4.
Rev. esp. reumatol. (Ed. impr.) ; 27(3): 112-115, mar. 2000.
Artigo em Espanhol | IBECS | ID: ibc-7489

RESUMO

Las artritis reactivas son episodios inflamatorios articulares que aparecen tras un proceso infeccioso, habitualmente intestinal o genital, no pudiéndose cultivar el germen del material obtenido en la articulación inflamada. La artritis reactiva tras infección de vías aéreas es infrecuente; en este sentido son pocos los casos descritos tras infección por Chlamydia pneumoniae. Se describen 3 pacientes que presentaron artritis, dos de ellos con infección de vías respiratorias altas previa al inicio de la artritis, sin evidencia de infección por los gérmenes habitualmente responsables de artritis reactiva ni de infección viral, con cultivos de líquido sinovial negativos y con seroconversión de los anticuerpos específicos para Chlamydia pneumoniae. Tras recibir tratamiento con tetraciclinas, el cuadro se resolvió completamente en los 3 pacientes. Existen muy pocos casos en la bibliografía científica que asocien Chlamydia pneumoniae como causa de artritis reactiva. Su similitud clínica con la fiebre reumática obliga a pensar en este germen como agente causal de toda artritis precedida por un cuadro de vías respiratorias y a iniciar un tratamiento antibiótico adecuado para evitar cronicidad y/o recidivas. (AU)


Assuntos
Adulto , Idoso , Feminino , Masculino , Humanos , Artrite Reativa/microbiologia , Infecções por Chlamydia , Doxiciclina/uso terapêutico , Chlamydophila pneumoniae , Antibacterianos/uso terapêutico , Seguimentos , Artrite Reativa/tratamento farmacológico , Artrite Reativa/diagnóstico , Infecções por Chlamydia/tratamento farmacológico , Infecções por Chlamydia/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA